JonesTrading Remains a Buy on Vascular Biogenics (VBLT)


JonesTrading analyst Soumit Roy reiterated a Buy rating on Vascular Biogenics (VBLT) today and set a price target of $3.75. The company’s shares closed last Monday at $1.16.

According to TipRanks.com, Roy is a 5-star analyst with an average return of 43.4% and a 58.4% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Actinium Pharmaceuticals.

Vascular Biogenics has an analyst consensus of Strong Buy, with a price target consensus of $3.75.

See today’s analyst top recommended stocks >>

The company has a one-year high of $1.64 and a one-year low of $0.90. Currently, Vascular Biogenics has an average volume of 529.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi’in, Israel.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts